+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
U.S. Androgenetic Alopecia Market Size, Share & Trends Analysis Report By Treatment (Pharmaceuticals, Devices), By Sales Channel (Prescriptions, OTC), By Gender, By End Use, And Segment Forecasts, 2025 - 2030- Product Image
U.S. Androgenetic Alopecia Market Size, Share & Trends Analysis Report By Treatment (Pharmaceuticals, Devices), By Sales Channel (Prescriptions, OTC), By Gender, By End Use, And Segment Forecasts, 2025 - 2030- Product Image
New

U.S. Androgenetic Alopecia Market Size, Share & Trends Analysis Report By Treatment (Pharmaceuticals, Devices), By Sales Channel (Prescriptions, OTC), By Gender, By End Use, And Segment Forecasts, 2025 - 2030

  • PDF Icon

    Report

  • 80 Pages
  • June 2025
  • Region: United States
  • Grand View Research
  • ID: 6111328
Description Jump to:

U.S. Androgenetic Alopecia Market Trends

The U.S. androgenetic alopecia market was valued at USD 979.1 million in 2024 and is expected to grow at a CAGR of 6.6% from 2025 to 2030. The increasing incidence of Androgenic Alopecia (AGA) is driving market growth. Androgenetic alopecia, the most common form of hair loss, affects a significant portion of the population, with aging and genetic factors playing a role. As awareness about hair loss solutions rises, more individuals seek treatments, expanding the market. According to data published by the National Library of Medicine in July 2023, approximately 50 million men and 30 million women in the U.S. were affected by androgenetic alopecia (AGA).

Another factor is the advancement in treatment options. The market has witnessed the introduction of innovative therapies, such as topical solutions, oral medications, and minimally invasive procedures such as platelet-rich plasma (PRP) therapy and hair transplant surgeries. Pharmaceutical companies also invest in research and development to create more effective and convenient treatments, attracting a broader consumer base.

The approval of new drugs and the expansion of over-the-counter products further propel market growth. In June 2025, Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405, a topical treatment targeting hair loss by reactivating dormant hair follicle stem cells. This advancement positions Pelage as a leader in regenerative medicine for androgenetic alopecia.

U.S. Androgenetic Alopecia Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, the analyst has segmented the U.S. androgenetic alopecia market report based on treatment, end use, sales channel, and gender:

Treatment Outlook (Revenue, USD Million, 2018 - 2030)

  • Pharmaceuticals
  • Devices

End Use Outlook (Revenue, USD Million, 2018 - 2030)

  • Homecare Settings
  • Dermatology Clinics

Sales Channel Outlook (Revenue, USD Million, 2018 - 2030)

  • Prescriptions
  • OTC

Gender Outlook (Revenue, USD Million, 2018 - 2030)

  • Male
  • Female

Why should you buy this report?

  • Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players worldwide.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listing for you to stay ahead of the curve
  • COVID-19's impact and how to sustain in these fast-evolving markets

This product will be delivered within 2 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Treatment
1.2.2. End Use
1.2.3. Sales Channel
1.2.4. Gender
1.2.5. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market formulation & Validation
1.7. Model Details
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Treatment Outlook
2.2.2. End Use Outlook
2.2.3. Sales Channel Outlook
2.2.4. Gender Outlook
2.3. Competitive Insights
Chapter 3. U.S. Androgenetic Alopecia Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. U.S. Androgenetic Alopecia Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrant
3.3.1.5. Competitive Rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political Landscape
3.3.2.2. Technological Landscape
3.3.2.3. Economic Landscape
3.4. U.S. Androgenetic Alopecia Market: Pipeline Analysis
Chapter 4. U.S. Androgenetic Alopecia Market: Treatment Estimates & Trend Analysis
4.1. Treatment Segment Dashboard
4.2. U.S. Androgenetic Alopecia Market: Treatment Movement Analysis
4.3. U.S. Androgenetic Alopecia Market Size & Trend Analysis, by Treatment, 2018 to 2030 (USD Million)
4.4. Pharmaceuticals
4.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
4.5. Devices
4.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
Chapter 5. U.S. Androgenetic Alopecia Market: End Use Estimates & Trend Analysis
5.1. End Use Segment Dashboard
5.2. U.S. Androgenetic Alopecia Market: End Use Movement Analysis
5.3. U.S. Androgenetic Alopecia Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
5.4. Homecare Settings
5.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
5.5. Dermatology Clinics
5.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
Chapter 6. U.S. Androgenetic Alopecia Market: Sales Channel Estimates & Trend Analysis
6.1. Sales Channel Segment Dashboard
6.2. U.S. Androgenetic Alopecia Market: Sales Channel Movement Analysis
6.3. U.S. Androgenetic Alopecia Market Size & Trend Analysis, by Sales Channel, 2018 to 2030 (USD Million)
6.4. Prescriptions
6.4.1. Market Estimates and Forecasts 2018 to 2030 (USD million)
6.5. OTC
6.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
Chapter 7. U.S. Androgenetic Alopecia Market: Gender Estimates & Trend Analysis
7.1. Male
7.1.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
7.2. Female
7.2.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company/Competition Categorization
8.3. Vendor Landscape
8.3.1. Key company heat map analysis, 2024
8.4. Company Profiles
8.4.1. Johnson & Johnson Services, Inc.
8.4.1.1. Company overview
8.4.1.2. Financial performance
8.4.1.3. Product benchmarking
8.4.1.4. Strategic initiatives
8.4.2. Cipla
8.4.2.1. Company overview
8.4.2.2. Financial performance
8.4.2.3. Product benchmarking
8.4.2.4. Strategic initiatives
8.4.3. Sun Pharmaceutical Industries Ltd.
8.4.3.1. Company overview
8.4.3.2. Financial performance
8.4.3.3. Product benchmarking
8.4.3.4. Strategic initiatives
8.4.4. Merck & Co., Inc
8.4.4.1. Company overview
8.4.4.2. Financial performance
8.4.4.3. Product benchmarking
8.4.4.4. Strategic initiatives
8.4.5. Dr. Reddy’s Laboratories Ltd.
8.4.5.1. Company overview
8.4.5.2. Financial performance
8.4.5.3. Product benchmarking
8.4.5.4. Strategic initiatives
8.4.6. Aurobindo Pharma Limited
8.4.6.1. Company overview
8.4.6.2. Financial performance
8.4.6.3. Product benchmarking
8.4.6.4. Strategic initiatives
8.4.7. Hairmax International LLC
8.4.7.1. Company overview
8.4.7.2. Financial performance
8.4.7.3. Product benchmarking
8.4.7.4. Strategic initiatives
8.4.8. Freedom Laser Therapy, Inc. (iRESTORE Hair Growth System)
8.4.8.1. Company overview
8.4.8.2. Financial performance
8.4.8.3. Product benchmarking
8.4.8.4. Strategic initiatives
8.4.9. Curallux, LLC
8.4.9.1. Company overview
8.4.9.2. Financial performance
8.4.9.3. Product benchmarking
8.4.9.4. Strategic initiatives
8.4.10. Apira Science, Inc. (iGROW Laser)
8.4.10.1. Company overview
8.4.10.2. Financial performance
8.4.10.3. Product benchmarking
8.4.10.4. Strategic initiatives
8.4.11. Theradome Inc.
8.4.11.1. Company overview
8.4.11.2. Financial performance
8.4.11.3. Product benchmarking
8.4.11.4. Strategic initiatives
List of Tables
Table 1 List of abbreviations
Table 2 U.S. androgenetic alopecia market, by treatment, 2018 - 2030 (USD Million)
Table 3 U.S. androgenetic alopecia market, by end use, 2018 - 2030 (USD Million)
Table 4 U.S. androgenetic alopecia market, by sales channel, 2018 - 2030 (USD Million)
Table 5 U.S. androgenetic alopecia market, by gender, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Primary interviews
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 U.S. androgenetic alopecia market: market outlook
Fig. 10 U.S. androgenetic alopecia competitive insights
Fig. 11 Parent market outlook
Fig. 12 Related/ancillary market outlook
Fig. 13 Penetration and growth prospect mapping
Fig. 14 Industry value chain analysis
Fig. 15 U.S. androgenetic alopecia market driver impact
Fig. 16 U.S. androgenetic alopecia market restraint impact
Fig. 17 U.S. androgenetic alopecia market strategic initiatives analysis
Fig. 18 U.S. androgenetic alopecia market: Treatment movement analysis
Fig. 19 U.S. androgenetic alopecia market: Treatment outlook and key takeaways
Fig. 20 Pharmaceuticals market estimates and forecast, 2018 - 2030
Fig. 21 Devices market estimates and forecast, 2018 - 2030
Fig. 22 U.S. androgenetic alopecia market: End Use movement analysis
Fig. 23 U.S. androgenetic alopecia market: End Use outlook and key takeaways
Fig. 24 Homecare settings market estimates and forecasts, 2018 - 2030
Fig. 25 Dermatology clinics market estimates and forecasts, 2018 - 2030
Fig. 26 U.S. androgenetic alopecia market: Sales channel movement analysis
Fig. 27 U.S. androgenetic alopecia market: Sales channel outlook and key takeaways
Fig. 28 Prescriptions market estimates and forecasts, 2018 - 2030
Fig. 29 OTC market estimates and forecasts, 2018 - 2030
Fig. 30 U.S. androgenetic alopecia market: Gender movement analysis
Fig. 31 U.S. androgenetic alopecia market: Gender outlook and key takeaways
Fig. 32 Male market estimates and forecasts, 2018 - 2030
Fig. 33 Female market estimates and forecasts, 2018 - 2030

Companies Mentioned

  • Johnson & Johnson Services, Inc.
  • Cipla
  • Sun Pharmaceutical Industries Ltd.
  • Merck & Co., Inc.
  • Dr. Reddy’s Laboratories Ltd.
  • Aurobindo Pharma Limited
  • Hairmax International, LLC
  • Freedom Laser Therapy, Inc. (iRESTORE Hair Growth System)
  • Curallux, LLC
  • Apira Science, Inc. (iGROW Laser)
  • Theradome Inc.

Table Information

Report AttributeDetails
No. of Pages80
PublishedJune 2025
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 979.1 Million
Forecasted Market Value ( USD ) by 2030 $ 1420 Million
Compound Annual Growth Rate6.6%
Regions CoveredUnited States
No. of Companies Mentioned11

Related Topics

Related Reports

Androgenetic Alopecia Market Size, Share & Trends Analysis Report By Gender (Male, Female), By Treatment (Pharmaceuticals, Devices), By End-use (Dermatology Clinics, Homecare Settings), By Sales Channel, And Segment Forecasts, 2024 - 2030 - Product Image

Androgenetic Alopecia Market Size, Share & Trends Analysis Report By Gender (Male, Female), By Treatment (Pharmaceuticals, Devices), By End-use (Dermatology Clinics, Homecare Settings), By Sales Channel, And Segment Forecasts, 2024 - 2030

  • Report
  • 150 Pages
  • Global
From
North America Alopecia Market Size, Share & Trends Analysis Report By Treatment (Pharmaceuticals, Devices), By Disease Type (Alopecia Areata), By End-use, By Sales Channel, By Gender, By Country, And Segment Forecasts, 2023-2030 - Product Image

North America Alopecia Market Size, Share & Trends Analysis Report By Treatment (Pharmaceuticals, Devices), By Disease Type (Alopecia Areata), By End-use, By Sales Channel, By Gender, By Country, And Segment Forecasts, 2023-2030

  • Report
  • 150 Pages
  • North America
From
Alopecia Market Size, Share & Trends Analysis Report By Disease Type (Alopecia Areata, Cicatricial, Traction, Androgenetic Alopecia), By Treatment, By Gender, By Sales Channel, By End Use, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Alopecia Market Size, Share & Trends Analysis Report By Disease Type (Alopecia Areata, Cicatricial, Traction, Androgenetic Alopecia), By Treatment, By Gender, By Sales Channel, By End Use, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 110 Pages
  • Global
From
Androgenetic Alopecia Market - Product Image

Androgenetic Alopecia Market

  • Report
  • 200 Pages
  • Global
From
North America Androgenetic Alopecia Market Size, Share & Trends Analysis Report By Treatment (Pharmaceuticals, and Devices), By Gender (Male, and Female), By Sales Channel, By Country and Growth Forecast, 2023 - 2030 - Product Image

North America Androgenetic Alopecia Market Size, Share & Trends Analysis Report By Treatment (Pharmaceuticals, and Devices), By Gender (Male, and Female), By Sales Channel, By Country and Growth Forecast, 2023 - 2030

  • Report
  • 119 Pages
  • North America
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.